Health technology firm Royal Philips has secured CE mark approval for its V60 Plus noninvasive ventilator.


Image: Philips V60 Plus enables clinicians to enhance patient outcomes with less invasive respiratory care therapies and improve clinician workflow. Photo: courtesy of Koninklijke Philips N.V.

Based on Philips’ noninvasive ventilation (NIV) gold standard platform, the V60 Plus ventilator incorporates both NIV and high flow therapy (HFT) in a single device.

The V60 Plus ventilator enables clinicians to quickly adjust therapies without shifting devices when patient conditions are constantly changing.

Philips has developed the ventilator for early intervention in respiratory failure, allowing clinicians to enhance patient outcomes with less invasive respiratory care therapies and improve clinician workflow.

According to the company, the early implementation of NIV will result in less endotracheal intubation and also reduces serious complications and adverse events in the ICU.

The V60 Plus will simplify both workflow and device availability, as it is having the different and complementary modes in one device. It also helps to deliver a range of non-invasive support for the patients.

The company has also submitted 510(k) application with the US Food and Drug Administration for the ventilator.

Philips hospital respiratory care business leader Jim Alwan said: “When treating respiratory patients in Intensive and Emergency Care settings, it’s critical for clinicians to be able to wean efficiently or to quickly escalate care depending on their patient’s condition and specific needs.

“We are excited to offer a comprehensive noninvasive solution that enables quick therapy and interface transitions, so clinicians can focus on providing for their patients while spending less time setting up equipment.”

In October this year, Philips collaborated with injection and infusion systems manufacturer Ypsomed for the development of new digital self-medication adherence monitoring services.

The services will be based on Philips’cloud-based HealthSuite digital platform and connected devices of Ypsomed.

The new SmartServices will allow injection systems manufacturer to expand its medical device business by offering digital solution for medication adherence monitoring and smart device management to its pharmaceutical customers.

Philips provides diagnostic imaging, image-guided therapy, patient monitoring and health informatics, consumer health and home care solutions.